USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Companion Diagnostics: Biomarker Platforms Enabling Precision Medicine
Unveiling One of the Most Promising Fields of Therapeutic Technology Synergy
13-Nov-2018
Global
Technology Research
D83E-01-00-00-00
HC03104-GL-TR_22527
$4,950.00
Special Price $3,712.50 save 25 %
Both predictive and prognostic biomarkers constitutes an central element in each and every targeted oncology drug discovery and development program. Breakthrough technologies allowing leveraging biomarkers for oncology are paving the way of personalized medicine and precision oncology. Indeed, oncology biomarkers provide the clinical community with the opportunity to offer individualized therapies and health programs. Furthermore, oncology biomarkers enable to get critical information about the mechanism of action of a drug or target, to profoundly study carcinogenesis process, and to match patient characteristics specifically to the most appropriate treatment.
1.1 Companion Diagnostics: The Bigger Picture
1.2 Research Focus: Advancing New Diagnostics and Therapeutics
1.3 Research Scope: Unveiling Novel Diagnostics Pathways
1.4 Analysis Framework: Frost & Sullivan’s Core Value
1.5 Research Methodology: Five Steps toward Success
2.1 Key Elements of Analysis: The ‘Companion Diagnostics’ Concept
2.2 Brief Overview of Companion Diagnostics
2.3 Effectiveness and Performance Validation for CDx
2.4 Overall Landscape of Cancer Companion Diagnostics
2.5 Precision Oncology Accelerated Pathway
2.6 Biomarker Stratification for Companion Diagnostics
2.7 Emerging Opportunities for Companion Diagnostics
3.1 Technology Synergy Reshaping Value Chain
3.2 Product Development and Commercialization
3.3 Technology and Business Landscape: Accelerators
3.4 Technology and Business Landscape: Challenges
3.5 New Approaches Driving Companion Diagnostics Solutions
4.1 Market Dynamics and Opportunities
4.2 Market Potential: Technology Focus Segmentation
4.3 Market Potential: Therapeutic Area and Regional Segmentation
4.4 Impact of Companion Diagnostics on Therapeutic Areas
4.5 Prominent Pharmaceutical Market Leaders
5.1 The Role of Stakeholders in Business Strategy
5.2 Technology Transfer Assessment and Perceptions
5.3 Disruptive Companion Diagnostics Solutions
5.4 Business Model Hybridization
5.5 Overall Environmental Impact Factors
5.6 Future Perspective for Companion Diagnostics
6.1 Key Funding and Investment Opportunities
6.2 Funding and Investment Models and Adoption
6.3 Funding Long Shots, Securitization, and Credit
6.4 Strategic Collaborations
7.1 Multicriteria Approach for Benchmarking
7.2 Strategic Portfolio Assessment
7.3 Level 1 Criteria: Innovation Development
7.4 Level 1 Criteria: Financial Performance
7.5 Level 1 Criteria: Market Evolution
7.6 Level 2 Criteria: Key Actions for Success
7.7 Analytic Performance Results
7.8 Multicriteria Final Assessment
7.9 Strategic Imperatives: Critical Success Factors
8.1 Key Industry Influencers
8.1 Key Industry Influencers (continued)
8.1 Key Industry Influencers (continued)
8.1 Key Industry Influencers (continued)
8.1 Key Industry Influencers (continued)
Legal Disclaimer
Speak directly with our analytics experts for tailored recommendations.
Recent related Healthcare research
27 Aug 2026 | Global | Frost Radar
Frost Radar: AI-Powered Molecular Diagnostics, 2026
AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, present...
26 Aug 2026 | Global | Technology Research
Growth Opportunities and Advancements in Acute and Chronic Wound Care
A wound is any disruption in the normal structure and function of the skin or underlying tissues. It can result from physical injury, surgery, or underlying medical conditions. Wounds are broadly classified into two categories: acute wounds and chronic wounds. Acute wounds typically heal through the...
26 Aug 2026 | Global | Frost Radar
Frost Radar™: Healthcare Infrastructure Cybersecurity in the United States, 2026
Healthcare organizations are expanding their digital environments across cloud infrastructure, connected medical devices, applications, identities, operational technology, and distributed care settings, creating a broader and increasingly interconnected attack surface. Cybersecurity is, therefore, e...
25 Aug 2026 | Global | Technology Research
Breakthrough Innovations in Point-of-Care Diagnostics
This research analyzes how point-of-care (PoC) diagnostics is evolving from simple tests to decentralized, connected, and clinically actionable testing platforms across hospitals, outpatient settings, homes, and pharmacies.
The study assesses key technology shifts, including rapid molecular t...
25 Aug 2026 | Global | Technology Research
Innovations and Growth Opportunities in Digital Biomarkers
A digital biomarker refers to measurable data about physiological functions or behaviors collected through digital devices and technologies, such as wearables, implants, ingestible sensors, smartphones, and mobile applications.
These biomarkers provide continuous, real-time insights into an ...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Technology Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Cecilia Van Cauwenberghe |
| Industries | Healthcare |
| WIP Number | D83E-01-00-00-00 |
| Is Prebook | No |
| Ti Codes | D901,D910,D913,D91A,D933,D935,D936,D937,D947-TI |
